6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Identification of the Tau phosphorylation pattern that drives its aggregation

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          In Alzheimer’s disease, the microtubule-associated protein Tau is invariably found in a hyperphosphorylated and aggregated form. Whether (hyper)phosphorylation can drive aggregation is less clear, and no precise phosphorylation pattern leading to aggregation has been described. Combining in vitro phosphorylation assays with purified kinases and a rat brain extract with the analytical power of NMR spectroscopy, we unravel here the phosphorylation pattern of Tau that drives its aggregation. The results point to the importance of this posttranslational modification in Tau's aggregation and suggest orienting therapeutic strategies toward phosphorylated Tau.

          Abstract

          Determining the functional relationship between Tau phosphorylation and aggregation has proven a challenge owing to the multiple potential phosphorylation sites and their clustering in the Tau sequence. We use here in vitro kinase assays combined with NMR spectroscopy as an analytical tool to generate well-characterized phosphorylated Tau samples and show that the combined phosphorylation at the Ser202/Thr205/Ser208 sites, together with absence of phosphorylation at the Ser262 site, yields a Tau sample that readily forms fibers, as observed by thioflavin T fluorescence and electron microscopy. On the basis of conformational analysis of synthetic phosphorylated peptides, we show that aggregation of the samples correlates with destabilization of the turn-like structure defined by phosphorylation of Ser202/Thr205.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer's mice.

          Amyloid-β (Aβ) toxicity in Alzheimer's disease (AD) is considered to be mediated by phosphorylated tau protein. In contrast, we found that, at least in early disease, site-specific phosphorylation of tau inhibited Aβ toxicity. This specific tau phosphorylation was mediated by the neuronal p38 mitogen-activated protein kinase p38γ and interfered with postsynaptic excitotoxic signaling complexes engaged by Aβ. Accordingly, depletion of p38γ exacerbated neuronal circuit aberrations, cognitive deficits, and premature lethality in a mouse model of AD, whereas increasing the activity of p38γ abolished these deficits. Furthermore, mimicking site-specific tau phosphorylation alleviated Aβ-induced neuronal death and offered protection from excitotoxicity. Our work provides insights into postsynaptic processes in AD pathogenesis and challenges a purely pathogenic role of tau phosphorylation in neuronal toxicity.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins.

            Tau protein is the major component of the intraneuronal filamentous inclusions that constitute defining neuropathological characteristics of Alzheimer's disease and other tauopathies. The discovery of tau gene mutations in familial forms of frontotemporal dementia has established that dysfunction of the tau protein is sufficient to cause neurodegeneration and dementia. Here we have tested 42 compounds belonging to nine different chemical classes for their ability to inhibit heparin-induced assembly of tau into filaments in vitro. Several phenothiazines (methylene blue, azure A, azure B, and quinacrine mustard), polyphenols (myricetin, epicatechin 5-gallate, gossypetin, and 2,3,4,2',4'-pentahydroxybenzophenone), and the porphyrin ferric dehydroporphyrin IX inhibited tau filament formation with IC(50) values in the low micromolar range as assessed by thioflavin S fluorescence, electron microscopy, and Sarkosyl insolubility. Disassembly of tau filaments was observed in the presence of the porphyrin phthalocyanine. Compounds that inhibited tau filament assembly were also found to inhibit the formation of Abeta fibrils. Biochemical analysis revealed the formation of soluble oligomeric tau in the presence of the inhibitory compounds, suggesting that this may be the mechanism by which tau filament formation is inhibited. The compounds investigated did not affect the ability of tau to interact with microtubules. Identification of small molecule inhibitors of heparin-induced assembly of tau will form a starting point for the development of mechanism-based therapies for the tauopathies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

              In Alzheimer disease (AD) the microtubule-associated protein tau is redistributed exponentially into paired helical filaments (PHFs) forming neurofibrillary tangles, which correlate with pyramidal cell destruction and dementia. Amorphous neuronal deposits and PHFs in AD are characterized by aggregation through the repeat domain and C-terminal truncation at Glu-391 by endogenous proteases. We show that a similar proteolytically stable complex can be generated in vitro following the self-aggregation of tau protein through a high-affinity binding site in the repeat domain. Once started, tau capture can be propagated by seeding the further accumulation of truncated tau in the presence of proteases. We have identified a nonneuroleptic phenothiazine previously used in man (methylene blue, MB), which reverses the proteolytic stability of protease-resistant PHFs by blocking the tau-tau binding interaction through the repeat domain. Although MB is inhibitory at a higher concentration than may be achieved clinically, the tau-tau binding assay was used to identify desmethyl derivatives of MB that have Ki values in the nanomolar range. Neuroleptic phenothiazines are inactive. Tau aggregation inhibitors do not affect the tau-tubulin interaction, which also occurs through the repeat domain. Our findings demonstrate that biologically selective pharmaceutical agents could be developed to facilitate the proteolytic degradation of tau aggregates and prevent the further propagation of tau capture in AD.
                Bookmark

                Author and article information

                Journal
                Proc Natl Acad Sci U S A
                Proc. Natl. Acad. Sci. U.S.A
                pnas
                pnas
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                22 August 2017
                7 August 2017
                : 114
                : 34
                : 9080-9085
                Affiliations
                [1] aUnité de Glycobiologie Structurale et Fonctionnelle, CNRS UMR 8576, Université de Lille , 59655 Villeneuve d'Ascq, France;
                [2] bLaboratoire des Biomolécules, CNRS UMR 7203, Sorbonne Universités, Université Pierre et Marie Curie, Ecole Normale Supérieure-Paris Sciences et Lettres Research University , 75252 Paris cedex 05, France;
                [3] cInstitut Baulieu, Inserm UMR 1195, Université Paris-Saclay, 94276 Le Kremlin Bicêtre, France;
                [4] dInserm UMR 1195, Université Paris-Saclay , 94276 Le Kremlin Bicêtre, France;
                [5] eLaboratoire d'Ingénierie des Systèmes Biologiques et des Procédés, CNRS, Institut National des Sciences Appliquées, Institut National de Recherche Agronomique , Université de Toulouse, 31077 Toulouse, France
                Author notes

                Contributed by Etienne-Emile Baulieu, July 10, 2017 (sent for review June 16, 2017; reviewed by Michel Goedert and Jürgen Götz)

                Author contributions: E.-E.B., Y.J., I.L., G.L., and C.S.-N. designed research; C.D., C.B., H.Q., F.-X.C., and I.H. performed research; C.B., H.Q., I.H., B.C., E.-E.B., and Y.J. contributed new reagents/analytic tools; C.D., I.L., G.L., and C.S.-N. analyzed data; and G.L. and C.S.-N. wrote the paper.

                Reviewers: M.G., MRC Laboratory of Molecular Biology; and J.G., The University of Queensland.

                Article
                PMC5576827 PMC5576827 5576827 201708448
                10.1073/pnas.1708448114
                5576827
                28784767
                af7fe168-0f48-4fda-aebe-1e0e53806107
                History
                Page count
                Pages: 6
                Categories
                Biological Sciences
                Biochemistry

                Tau,phosphorylation,aggregation,Alzheimer’s disease,NMR
                Tau, phosphorylation, aggregation, Alzheimer’s disease, NMR

                Comments

                Comment on this article